Semantic Scholar uses AI to extract papers important to this topic.
Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical… Expand PURPOSE This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses of… Expand Acute graft-versus-host disease (aGVHD) is the primary limitation of allogeneic hematopoietic cell transplantation… Expand Objective: To review FDA approved and other potential uses of Ontak, denileukin diftitox. Methods: Information was obtained via… Expand CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… Expand Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria… Expand Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… Expand In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB… Expand PURPOSE
The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox… Expand We have genetically replaced the diphtheria toxin receptor binding domain with a synthetic gene encoding interleukin-2 (IL-2) and… Expand